Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Ultragenyx Pharmaceutical Inc. (RARE)Newsfile Corp • 01/14/26
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare ConferenceGlobeNewsWire • 01/12/26
RARE Rises on Completion of Rolling Submission for AAV Gene TherapyZacks Investment Research • 12/31/25
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 12/30/25
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary EndpointZacks Investment Research • 12/30/25
These biotech stocks are getting hammered by shocking brittle-bone treatment study resultsMarket Watch • 12/29/25
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis ImperfectaGlobeNewsWire • 12/29/25
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor HoldingsSeeking Alpha • 12/15/25
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 EarningsZacks Investment Research • 11/04/25
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life SciencesGlobeNewsWire • 11/04/25
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 10/28/25
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/28/25